Get the Stockscreener App
1.64
6.82%
-0.12
Acrivon Therapeutics Inc stock is traded at $1.64, with a volume of 261.18K.
It is down -6.82% in the last 24 hours and down -3.53% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
See More
Previous Close:
$1.76
Open:
$1.75
24h Volume:
261.18K
Relative Volume:
0.98
Market Cap:
$70.28M
Revenue:
Net Income/Loss:
$-77.27M
P/E Ratio:
-0.8192
EPS:
-2.0019
Net Cash Flow:
$-66.29M
1W Performance:
-14.14%
1M Performance:
-3.53%
6M Performance:
-1.80%
1Y Performance:
-12.30%
1-Day Range:
$1.63
$1.77
1-Week Range:
$1.63
$1.9292
52-Week Range:
$1.27
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.64 | 70.28M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics chief legal officer sells $585 in stock - Investing.com
Form 4 Acrivon Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
Mary Miller Executes Automatic Sale of 294 Shares at $1.99 for RSU Tax Withholding at Acrivon Therapeutics - Kalkine Media
Automatic tax withholding triggers a 294-share sale by Acrivon Therapeutics (ACRV) legal chief - Stock Titan
Form 4 Acrivon Therapeutics Inc For: 7 October By Investing.com - Investing.com Nigeria
Acrivon Therapeutics chief legal officer sells $585 in stock By Investing.com - Investing.com UK
ACRV 8-K & SEC Filings - Yahoo Finance Australia
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com Canada
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com India
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com UK
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - The Manila Times
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Acrivon Therapeutics files Form 3 for Chief Business Officer Michaela Levin - Bitget
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Nigeria
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com India
Acrivon Therapeutics Names Michaela Levin Chief Business Officer - citybiz
acrivon appoints michaela levin as chief business officer - investing.com
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Canada
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com UK
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - GlobeNewswire
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - The Manila Times
ACRV Q2 2026 Earnings: Narrower-Than-Expected Loss in a Pre-Revenue QuarterProfit Margin Analysis - vinanet.vn
Acrivon (NASDAQ: ACRV) CEO sells 14K shares to cover RSU taxes - Stock Titan
Acrivon (NASDAQ: ACRV) CEO may sell stock from vested RSUs - Stock Titan
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Acrivon Therapeutics (ACRV) CLO sells 185 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
Acrivon (NASDAQ: ACRV) chiefs sell shares to cover RSU taxes - Stock Titan
Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the DayFull Year Guidance - vinanet.vn
ACRV Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 5.9%Capex Guidance - vinanet.vn
Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat
ACRV Q1 2026 Earnings: Loss Narrower Than Expected, Stock Advances 5.41%Forward EPS Estimate - Vinanet
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat
Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks
Acrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M - scanx.trade
Acrivon Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Imbalance Zone - Vinanet
Acrivon Therapeutics Q2 net loss narrows as costs decline - TradingView
BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 Million - TradingView
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewswire
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Island Reversal - dars.gov.et
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peter Blume-Jensen | Officer |
Aug 25 '26 |
Proposed Sale |
2.18 |
14,036 |
30,598 |
0 |
| Blume-Jensen Peter | President and CEO |
Aug 25 '26 |
Sale |
2.21 |
14,036 |
30,969 |
2,230,052 |
| Miller Mary | Chief Legal Officer |
Aug 18 '26 |
Sale |
2.01 |
185 |
372 |
82,009 |
| Gamelin Erick | Chief Development Officer |
Aug 18 '26 |
Sale |
2.01 |
400 |
804 |
52,592 |
| Devroe Eric | Chief Operating Officer |
Aug 18 '26 |
Sale |
2.01 |
604 |
1,214 |
146,349 |
| Blume-Jensen Peter | President and CEO |
Aug 18 '26 |
Sale |
2.01 |
484 |
973 |
385,859 |
| Blume-Jensen Peter | President and CEO |
Aug 18 '26 |
Sale |
2.01 |
1,229 |
2,470 |
2,244,088 |
| Peterson Katharine | Chief Accounting Officer |
Aug 18 '26 |
Sale |
2.01 |
101 |
203 |
18,033 |
| Levy Adam D. | Chief Financial Officer |
Aug 04 '26 |
Sale |
1.57 |
1,142 |
1,793 |
66,008 |
| Miller Mary | Chief Legal Officer |
Jul 21 '26 |
Sale |
1.76 |
573 |
1,008 |
82,194 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):